BRUKER CORPORATION (NASDAQ:BRKR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On December 5, 2016, René Lenggenhager, President of the Bruker BioSpin Group, notified Bruker Corporation (the “Company”) that he will be leaving the Company, effective on or about February 24, 2017, in order to become the chief executive officer of COMET-Group AG, a publicly-traded Swiss company. Until such time, Dr. Lenggenhager will continue to serve as Bruker BioSpin Group President. The Company intends to initiate a search for a successor to Dr. Lenggenhager.